Peter‐Andreas Löschmann

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

Lechosław Turski, Karin Bressler, Klaus Jürgen Rettig et al. · Nature · 1991 · 549 citations

Substantia Nigra, Medicine, Psychotropic Medication +9

Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease

Peter‐Andreas Löschmann, Carmen de Groote, Lance A. Smith et al. · Experimental Neurology · 2004 · 99 citations

Medicine, Animal Models, Neuropharmacology +8

Kainate Microinjection into the Dorsal Raphe Nucleus Induces 5-HT Release in the Amygdala and Periaqueductal Gray

Milena de Barros Viana, Frederico Guilherme Graeff, Peter‐Andreas Löschmann · Pharmacology Biochemistry and Behavior · 1997 · 74 citations

5-Ht Release, Neurobiological Mechanism, Neurophysiology +12

Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice

Andreas Kupsch, Peter‐Andreas Löschmann, H. Sauer et al. · Brain Research · 1992 · 70 citations

Neuropeptides, Medicine, Immunology +11

NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy- piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats

H. Wachtel, Margrit Kunow, Peter‐Andreas Löschmann · Neuroscience Letters · 1992 · 58 citations

Substantia Nigra, Neurophysiology, Medicine +10